Annovis Bio, Inc. ANVS
Annovis Bio, Inc. (NYSE: ANVS) is a CNS/neurology/psychiatry drug developer. Its lead program, Buntanetap, is in Phase 3 for Early Alzheimer's disease. Its next catalyst on record is Buntanetap: Pivotal Phase 3 AD readout (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Buntanetap — Pivotal Phase 3 AD readout (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Buntanetap | Early Alzheimer's disease (NCT06709014) | small molecule | Phase 3 |
| Buntanetap | Parkinson's disease open-label extension (NCT07284784) | small molecule | Phase 3 |
| Buntanetap | Alzheimer's open-label extension | small molecule | Phase 3 |
| Buntanetap | Parkinson's disease dementia | small molecule | Phase 2 |
Recent results and decisions
- Jul 7, 2026completed enrollment Pivotal Phase 3 AD trial fully enrolled with 850 patients, above the 760 target.
today announced full enrollment of its pivotal Phase 3 trial (NCT06709014) evaluating buntanetap in patients with early AD.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.